This mdr is being submitted due to the reported seroma formation after initial placement of the acell device.The device was not explanted and is performing as expected.A review of the manufacturing records for this lot identified no deviations in the production process that fall outside of specification.The device was manufactured and distributed sterile in compliance with acell's operating procedures and federal, state, and local laws and regulations.
|
On 10/21/2020, acell, inc.Was notified that a gentrix device was partially explanted due a seroma.The gentrix device was implanted on (b)(6) 2020 due to a recurrent incisional hernia; a prior mesh sepramesh was removed at this time.The gentrix was placed in the recto-rectus spaced with a drain.Patient had a pre-existing infection where the gentrix was placed.On (b)(6) 2020 the patient was shown to have fluid building up above the device, surgeon reoperated and debrided area around gentrix device.The majority of the acell device (>90%) remains in the retrorectus space and is functioning as intended.
|